EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis.

There was a tendency of prolonged OS of combination therapy versus monotherapy with 3rd generation TKIs, though the difference did not reach statistical significance (NA vs. 43.8 months, p = 0.171; Fig. 3 L).

also in 111,027 other papers